Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NR50
UPID:
EI2BG_HUMAN
Alternative names:
eIF-2B GDP-GTP exchange factor subunit gamma
Alternative UPACC:
Q9NR50; B2RBH8; D3DPZ2; Q5QP89; Q5QP90; Q8NDB5; Q8WV57; Q9H850
Background:
Translation initiation factor eIF-2B subunit gamma, also known as eIF-2B GDP-GTP exchange factor subunit gamma, plays a crucial role in protein synthesis by catalyzing the exchange of eukaryotic initiation factor 2-bound GDP for GTP. This process is vital for the initiation phase of protein synthesis, making it a key player in cellular function and health.
Therapeutic significance:
Leukoencephalopathy with vanishing white matter 3, a progressive brain disease, is linked to mutations affecting this protein. Understanding the role of Translation initiation factor eIF-2B subunit gamma could open doors to potential therapeutic strategies for this debilitating condition, highlighting its importance in medical research.